Citations

Clear

6274 citation(s) found for "To, Andrew".

Technological advances in elite marathon performance
Senefeld, Jonathon W. , Haischer, Michael H. , Jones, Andrew M. , Wiggins, Chad C. , Beilfuss, Rachel, Joyner, Michael J. , Hunter, Sandra K. , Hunter, Sandra K , Jones, Andrew M , Wiggins, Chad C , Joyner, Michael J , Senefeld, Jonathon W

Mayo Clinic

Journal of Applied Physiology | May 13, 2021 | Volume: 130 | Issue: 6 | Pages: 2002-2008

10.1152/japplphysiol.00002.2021 | PMID 33982594 Get It

World-class athletes are substantively faster, wearing marathon racing shoes with technological advancements than other shoes when competing in the marathon. Our findings suggest that technological advances in footwear contributed to the recent improvements in marathon finishing times among elite runners and in record-setting marathon performances. This investigation highlights the importance of sports analytics and may have broad implications for the regulation of running footwear during competition.
Urinary NGAL as a Diagnostic and Prognostic Marker for Acute Kidney Injury in Cirrhosis: A Prospective Study
Allegretti, Andrew S. , Endres, Paul , Zhao, Sophia , Krinsky, Scott, Hillien, Shelsea A. St., Kalim, Sahir , Nigwekar, Sagar U. , Flood, James G., Nixon, Andrea, Simonetto, Douglas A. , Juncos, Luis A. , Karakala, Nithin , Wadei, Hani M. , Regner, Kevin R. , Belcher, Justin M. , Nadim, Mitra K. , García–Tsao, Guadalupe , Velez, Juan Carlos Q. , Parikh, Samir M. , investigators, on behalf of the HRS-HARMONY study, Simonetto, Douglas A , Wadei, Hani M , Juncos, Luis A , Parada, Xavier Fernando Vela , Chung, Raymond T. , investigators, on behalf of the HRS-HARMONY study

Mayo Clinic

Clinical and Translational Gastroenterology | May 12, 2021 | Volume: 12 | Issue: 5 | Pages: e00359

10.14309/ctg.0000000000000359 | PMID 33979307 Get It

INTRODUCTION: Urinary neutrophil gelatinase-associated lipocalin (NGAL) has shown promise in differentiating acute tubular necrosis (ATN) from other types of acute kidney injuries (AKIs) in cirrhosis, particularly hepatorenal syndrome (HRS). However, NGAL is not currently available in clinical practice in North America. METHODS: Urinary NGAL was measured in a prospective cohort of 213 US hospitalized patients with decompensated cirrhosis (161 with AKI and 52 reference patients without AKI). NGAL was assessed for its ability to discriminate ATN from non-ATN AKI and to predict 90-day outcomes. RESULTS: Among patients with AKI, 57 (35%) had prerenal AKI, 55 (34%) had HRS, and 49 (30%) had ATN, with a median serum creatinine of 2.0 (interquartile range 1.5, 3.0) mg/dL at enrollment. At an optimal cutpoint of 244 μg/g creatinine, NGAL distinguished ATN (344 [132, 1,429] μg/g creatinine) from prerenal AKI (45 [0, 154] μg/g) or HRS (110 [50, 393] μg/g; P < 0.001), with a C statistic of 0.762 (95% confidence interval 0.682, 0.842). By 90 days, 71 of 213 patients (33%) died. Higher median NGAL was associated with death (159 [50, 865] vs 58 [0, 191] μg/g; P < 0.001). In adjusted and unadjusted analysis, NGAL significantly predicted 90-day transplant-free survival ( P < 0.05 for all Cox models) and outperformed Model for End-Stage Liver Disease score by C statistic (0.697 vs 0.686; P = 0.04), net reclassification index (37%; P = 0.008), and integrated discrimination increment (2.7%; P = 0.02). DISCUSSION: NGAL differentiates the type of AKI in cirrhosis and may improve prediction of mortality; therefore, it holds potential to affect management of AKI in cirrhosis.
Reply: Adoption of Antifibrotic Medications: A Closer Look at the Data
Dempsey, Timothy , Payne, Stephanie , Sangaralingham, Lindsey R. , Dempsey, Timothy M , Sangaralingham, Lindsey, Limper, Andrew H.

Mayo Clinic

Annals of the American Thoracic Society | May 12, 2021 | Volume: 18 | Issue: 10 | Pages: 1757-1757

10.1513/annalsats.202104-516le | PMID 33979273 Get It

Stereotactic Radiosurgery for Differentiated Thyroid Cancer Brain Metastases: An International, Multicenter Study
Fribance, Sarah , Pikis, Stylianos , Lee, John Y. K. , Buch, Love, Bernstein, Kenneth , Mathieu, David , Perron, Rémi, Patel, Samir , Álvarez, Roberto Martínez , Moreno, Nuria Martínez , Lee, Cheng‐Chia , Strickland, Ben A. , Zada, Gabriel , Chang, Eric L. , Kondziolka, Douglas , Sheehan, Jason P. , Mathieu, David , Kondziolka, Douglas , Bunevičius, Adomas , Moran, Michael, Yang, Andrew I. , Liščák, Roman , Šimonová, Gabriela , Trifiletti, Daniel M. , Yang, Huai‐Che

Mayo Clinic

Thyroid® | May 12, 2021 | Volume: 31 | Issue: 8 | Pages: 1244-1252

10.1089/thy.2020.0947 | PMID 33978475 Get It

Background: Brain metastases (BM) from differentiated thyroid cancer are rare. Stereotactic radiosurgery (SRS) is commonly used for the treatment of BMs; however, the experience with SRS for thyroid cancer BMs remains limited. The goal of this international, multi-centered study was to evaluate the efficacy and safety of SRS for thyroid cancer BMs. Methods: From 10 institutions participating in the International Radiosurgery Research Foundation, we pooled patients with established papillary or follicular thyroid cancer diagnosis who underwent SRS for histologically confirmed or radiologically suspected BMs. We investigated patient overall survival (OS), local tumor control, and adverse radiation events (AREs). Results: We studied 42 (52% men) patients who underwent SRS for 122 papillary (83%) or follicular (17%) thyroid cancer BMs. The mean age at SRS was 59.86 ± 12.69 years. The mean latency from thyroid cancer diagnosis to SRS for BMs was 89.05 ± 105.49 months. The median number of BMs per patient was 2 (range: 1–10 BMs). The median SRS treatment volume was 0.79 cm 3 (range: 0.003–38.18 cm 3 ), and the median SRS prescription dose was 20 Gy (range: 8–24 Gy). The median survival after SRS for BMs was 14 months (range: 3–58 months). The OS was significantly shorter in patients harboring ≥2 BMs, when compared with patients with one BM (Log-rank = 5.452, p = 0.02). Two or more BMs (odds ratio [OR] = 3.688; confidence interval [CI]: 1.143–11.904; p = 0.03) and lower Karnofsky performance score at the time of SRS (OR = 0.807; CI: 0.689–0.945; p = 0.008) were associated with shorter OS. During post-SRS imaging follow-up of 25.21 ± 30.49 months, local failure (progression and/or radiation necrosis) of BMs treated with SRS was documented in five (4%) BMs at 7.2 ± 7.3 months after the SRS. At the last imaging follow-up, the majority of patients with available imaging data had stable intracranial disease (33%) or achieved complete (26%) or partial (24%) response. There were no clinical AREs. Post-SRS peritumoral T2/fluid attenuated inversion recovery signal hyperintensity was noted in 7% BMs. Conclusion: The SRS allows durable local control of papillary and follicular thyroid cancer BMs in the vast majority of patients. Higher number of BMs and worse functional status at the time of SRS are associated with shorter OS in patients with thyroid cancer BMs. The SRS is safe and is associated with a low risk of AREs.
Evidence-Based Health Informatics as the Foundation for the COVID-19 Response: A Joint Call for Action
Kushniruk, André, Georgiou, Andrew , Petersen, Carolyn , Ronquillo, Charlene , Paton, Chris , Nøhr, Christian , Skiba, Diane J., Huesing, Elaine, Gabarrón, Elia , Magrabi, Farah , Peute, Linda , Topaz, Max, Al-Shorbaji, Najeeb , Lacroix, Paulette, Cornet, Ronald , Gogia, Shashi Bhushan , Kobayashi, Shinji , Iyengar, Sriram , Mettler, Tobias , Vimarlund, Vivian , Petersen, Carolyn , Fernández-Luque, Luis , Basu, Arindam , Kuziemsky, Craig E. , Alhuwail, Dari , Borycki, Elizabeth M. , Denecke, Kerstin , Marcilly, Romaric , Deserno, Thomas M , Zhu, Xinxin

Mayo Clinic

Methods of Information in Medicine | May 11, 2021 | Volume: 59 | Issue: 06 | Pages: 183-192

10.1055/s-0041-1726414 | PMID 33975375 Get It

Abstract Background As a major public health crisis, the novel coronavirus disease 2019 (COVID-19) pandemic demonstrates the urgent need for safe, effective, and evidence-based implementations of digital health. The urgency stems from the frequent tendency to focus attention on seemingly high promising digital health interventions despite being poorly validated in times of crisis. Aim In this paper, we describe a joint call for action to use and leverage evidence-based health informatics as the foundation for the COVID-19 response and public health interventions. Tangible examples are provided for how the working groups and special interest groups of the International Medical Informatics Association (IMIA) are helping to build an evidence-based response to this crisis. Methods Leaders of working and special interest groups of the IMIA, a total of 26 groups, were contacted via e-mail to provide a summary of the scientific-based efforts taken to combat COVID-19 pandemic and participate in the discussion toward the creation of this manuscript. A total of 13 groups participated in this manuscript. Results Various efforts were exerted by members of IMIA including (1) developing evidence-based guidelines for the design and deployment of digital health solutions during COVID-19; (2) surveying clinical informaticians internationally about key digital solutions deployed to combat COVID-19 and the challenges faced when implementing and using them; and (3) offering necessary resources for clinicians about the use of digital tools in clinical practice, education, and research during COVID-19. Discussion Rigor and evidence need to be taken into consideration when designing, implementing, and using digital tools to combat COVID-19 to avoid delays and unforeseen negative consequences. It is paramount to employ a multidisciplinary approach for the development and implementation of digital health tools that have been rapidly deployed in response to the pandemic bearing in mind human factors, ethics, data privacy, and the diversity of context at the local, national, and international levels. The training and capacity building of front-line workers is crucial and must be linked to a clear strategy for evaluation of ongoing experiences.
Histological evaluation of acute ischemic stroke thrombi may indicate the occurrence of vessel wall injury during mechanical thrombectomy
Mereuta, Oana Madalina , Abbasi, Mehdi , Fitzgerald, Seán , Dai, Daying , Kadirvel, Ram , Almekhlafi, Mohammed , Kvamme, Peter , Gounis, Matthew J. , Patel, Biraj M. , Aghaebrahim, Amin, Sauvageau, Eric , Bhuva, Parita, Soomro, Jazba , Thacker, Ike, Copelan, Alexander , Nazari, Pouya , Cantrell, Donald R. , Mohammaden, Mahmoud , Pisani, Leonardo , Puri, Ajit S , Meves, Alexander , Larco, Jorge Arturo , Cloft, Harry J. , Kallmes, David F. , Doyle, Karen , Brinjikji, Waleed , Almekhlafi, Mohammed A , Mendes Pereira, Vitor , Jahromi, Babak S , Gounis, Matthew J , Nazari, Pouya , Al-Bayati, Alhamza , Pisani, Leonardo , Rodrigues, Gabriel Martins , Arturo Larco, Jorge L , Savastano, Luis , Doyle, Karen M , Brinjikji, Waleed , Patel, Biraj M , Fitzgerald, Seán , Dai, Daying , Madalina Mereuta, Oana , Kadirvel, Ramanathan , Hanel, Ricardó A. , Yoo, Albert J. , Layton, Kennith F. , Almandoz, Josser E Delgado , Jahromi, Babak S. , Nogueira, Raul G. , Demchuk, Andrew M. , Kayan, Yasha , Haussen, Diogo C , Al‐Bayati, Alhamza R , Entwistle, John

Mayo Clinic

Journal of NeuroInterventional Surgery | May 11, 2021 | Volume: 14 | Issue: 4 | Pages: 356-361

10.1136/neurintsurg-2021-017310 | PMID 33975922 Get It

Background Several animal studies have demonstrated that mechanical thrombectomy (MT) for acute ischemic stroke (AIS) may cause vessel wall injury (VWI). However, the histological changes in human cerebral arteries following MT are difficult to determine. Objective To investigate the occurrence of VWI during MT by histological and immunohistochemical evaluation of AIS clots. Methods As part of the multicenter STRIP registry, 277 clots from 237 patients were analyzed using Martius Scarlett Blue stain and immunohistochemistry for CD34 (endothelial cells) and smooth muscle actin (smooth muscle cells). Results MT devices used were aspiration catheters (100 cases), stentriever (101 cases), and both (36 cases). VWI was found in 33/277 clots (12%). There was no significant correlation between VWI and MT device. The degree of damage varied from grade I (mild intimal damage, 24 clots), to grade II (relevant intimal and subintimal damage, 3 clots), and III (severe injury, 6 clots). VWI clots contained significantly more erythrocytes (p=0.006*) and less platelets/other (p=0.005*) than non-VWI clots suggesting soft thrombus material. Thrombolysis correlated with a lower rate of VWI (p=0.04*). VWI cases showed a significantly higher number of passes (2 [1–4] vs 1 [1–3], p=0.028*) and poorer recanalization outcome (p=0.01*) than cases without VWI. Conclusions Histological markers of VWI were present in 12% of AIS thrombi, suggesting that VWI might be related to MT. VWI was associated with soft thrombus consistency, higher number of passes and poorer revascularization outcome. There was no significant correlation between VWI and MT device.
Genetically Predicted Circulating C-Reactive Protein Concentration and Colorectal Cancer Survival: A Mendelian Randomization Consortium Study
Hua, Xinwei , Lindström, Sara , Harrison, Tabitha A. , Alwers, Elizabeth , Berndt, Sonja I. , Brenner, Hermann , Buchanan, Daniel D. , Casey, Graham , Chang‐Claude, Jenny , Gallinger, Steven , Goldberg, Richard M. , Gunter, Marc J. , Hoffmeister, Michael , Joshi, Amit D. , Murphy, Neil , Pai, Rish K. , Shi, Qian , Slattery, Martha L. , Song, Mingyang , Peters, Ulrike , Harrison, Tabitha A , Brenner, Hermann , Buchanan, Daniel D , Campbell, Peter T , Chang-Claude, Jenny , Giles, Graham G , Goldberg, Richard M , Hoffmeister, Michael , Milne, Roger L , Pai, R K , Sakoda, Lori C , Schoen, Robert E , Slattery, Martha L , Peters, Ulrike , Gunter, Marc J , Shi, Qian , Murphy, Neil , Song, Mingyang , Dai, James Y. , Lin, Yi , Alberts, Steven R. , Campbell, Peter T. , Giles, Graham G. , Jenkins, Mark A. , Ma, Wenjie , Milne, Roger L. , Sakoda, Lori C. , Schoen, Robert E. , White, Emily E. , Marchand, Loı̈c Le , Chan, Andrew T. , Newcomb, Polly A.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | May 10, 2021 | Volume: 30 | Issue: 7 | Pages: 1349-1358

10.1158/1055-9965.epi-20-1848 | PMID 33972368 Get It

Abstract Background: A positive association between circulating C-reactive protein (CRP) and colorectal cancer survival was reported in observational studies, which are susceptible to unmeasured confounding and reverse causality. We used a Mendelian randomization approach to evaluate the association between genetically predicted CRP concentrations and colorectal cancer–specific survival. Methods: We used individual-level data for 16,918 eligible colorectal cancer cases of European ancestry from 15 studies within the International Survival Analysis of Colorectal Cancer Consortium. We calculated a genetic-risk score based on 52 CRP-associated genetic variants identified from genome-wide association studies. Because of the non-collapsibility of hazard ratios from Cox proportional hazards models, we used the additive hazards model to calculate hazard differences (HD) and 95% confidence intervals (CI) for the association between genetically predicted CRP concentrations and colorectal cancer–specific survival, overall and by stage at diagnosis and tumor location. Analyses were adjusted for age at diagnosis, sex, body mass index, genotyping platform, study, and principal components. Results: Of the 5,395 (32%) deaths accrued over up to 10 years of follow-up, 3,808 (23%) were due to colorectal cancer. Genetically predicted CRP concentration was not associated with colorectal cancer–specific survival (HD, −1.15; 95% CI, −2.76 to 0.47 per 100,000 person-years; P = 0.16). Similarly, no associations were observed in subgroup analyses by stage at diagnosis or tumor location. Conclusions: Despite adequate power to detect moderate associations, our results did not support a causal effect of circulating CRP concentrations on colorectal cancer–specific survival. Impact: Future research evaluating genetically determined levels of other circulating inflammatory biomarkers (i.e., IL6) with colorectal cancer survival outcomes is needed.
Abstract 15324: Mavacamten Favorably Impacts Key Pathophysiologic Processes in Obstructive Hypertrophic Cardiomyopathy: Results From the EXPLORER-HCM Study
Abraham, Theodore P. , Sehnert, Amy J. , Solomon, Scott D. , Lester, Steven J., Hegde, Sheila M. , Jacoby, Daniel Louis , Wang, Andrew , Ho, Carolyn Y. , Li, Wanying, Solomon, Scott David , Olivotto, Iacopo

Mayo Clinic

Circulation | May 10, 2021 | Volume: 142 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.142.suppl_3.15324 Get It

Introduction: Obstructive hypertrophic cardiomyopathy (oHCM) is characterized by dynamic LV outflow tract (LVOT) obstruction resulting from ventricular hypertrophy and mitral valve systolic anterior motion (SAM), and by elevated left ventricular (LV) filling pressures, all of which result in a significant morbidity despite medical therapy. Mavacamten (Mava) is a novel inhibitor of cardiac myosin that significantly reduces LVOT gradients in oHCM, noted initially in the phase 2 PIONEER and more recently in the phase 3 EXPLORER-HCM studies. Additional echocardiographic analyses were performed to investigate the effect of Mava on focused measures of cardiac structure and function in oHCM. Methods: EXPLORER-HCM (NCT03470545) was a multicenter, double-blind, placebo-controlled, phase 3 study that randomized symptomatic oHCM patients (LV ejection fraction ≥55% and resting and/or provoked LVOT gradient ≥50 mmHg) 1:1 to Mava vs placebo for 30 weeks. Echocardiograms were performed serially every 2-4 weeks over 30 weeks. Results: In total, 251 patients with oHCM were enrolled and 244 patients completed the study (mean age 58.5; 40.6% female). Compared to placebo, 30-week treatment with Mava led to significant reductions in LA volume index (-7.5 ml/m 2 , p<0.0001), lateral E/e’ (-3.8, p<0.0001), septal E/e’ (-3.4, p<0.0001), and LV mass index (-15.5 g/m 2 , p<0.0001) ( Table ). Significantly more Mava-treated patients achieved resolution of mitral valve SAM compared to placebo (80.9% vs 34.0% of patients; difference of 46.8%; p<0.0001) and mitral regurgitation (MR) (9.0% vs 0.0% of patients; difference of 9.0%; p=0.0006). Conclusions: Treatment with Mava for 30 weeks led to improvement in LV hypertrophy and markers of left-sided filling pressures (LA volume and E/e’). Furthermore, Mava treatment was associated with reduction of SAM and MR. These findings suggest that Mava has beneficial effects on several adverse pathophysiologic processes that are hallmarks of oHCM.
Abstract 14663: High Rate of Arrhythmia Diagnoses Following Return of Pathogenic/likely Pathogenic Variants in an Unselected Population
Davogustto, Giovanni , Shaffer, Christian M., Ning, Shang, Pacheco, Jennifer , Rinke, Lauren Lee, Kalash, Olivia R., Yoneda, Zachary T. , Kroncke, Brett M. , Iftikhar, Kullo, Larson, Eric B. , Manolio, Teri A. , Schaid, Daniel J. , Namjou, Bahram , George, Albert R., Leppig, Kathleen A. , Sleiman, Patrick, Sohn, Sunghwan , Wei, Wei‐Qi, Shoemaker, M. Benjamin , Roden, Dan M. , Glazer, Andrew M. , Farber‐Eger, Eric , Dikilitas, Ozan , Ning, Shang, Mosley, Jonathan D , Driest, Sara L. Van , Wells, Quinn S. , Wada, Yuko , Bland, Harris T. , Jarvik, Gail P. , Gordon, Adam, Mirshahi, Tooraj , Luo, Jonathan Z. , Alsaied, Tarek , Singh, Rajbir , Singhal, Ashutosh , Ralston, James D. , McNally, Elizabeth M. , George, Albert, Chung, Wendy K. , Carrell, David , Håkonarson, Håkon , Glessner, Joseph , Denny, Joshua C. , Roden, Dan M.

Mayo Clinic

Circulation | May 10, 2021 | Volume: 142 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.142.suppl_3.14663 Get It

Background: Return of incidental genetic findings is recommended for pathogenic/likely pathogenic (P/LP) variants in Mendelian arrhythmia genes. The extent to which these variants are associated with arrhythmia phenotypes in unselected populations is unknown. Objective: Assess the impact of return of results (RoR) of P/LP variants in 4 arrhythmia genes in research participants not selected for cardiovascular disease. Methods: The cohort included 24,410 participants from the Electronic Medical Records and Genomics Network. Rare variants (minor allele frequency <1%) in KCNE1 , KCNH2 , KCNQ1 , and SCN5A were identified and classified according to ACMG guidelines. Arrhythmia phenotypes extracted from electronic health records (EHRs) included atrial fibrillation/flutter (AF/AFL), conduction system disease, long QT syndrome (LQTS), ventricular tachycardia/fibrillation (VT/VF), and premature ventricular contractions (PVCs). P/LP carriers’ phenotypes were compared to non-carriers using logistic regression adjusted for demographic covariates and site. Participants with P/LP variants were informed of their results and the impact of this RoR was assessed after 1 year of follow-up clinical care. Results: The participants included 53.7% females and 72.5% white individuals, with a median age of 57 years. 71 participants had a heterozygous P/LP variant in one of the 4 genes. LQTS diagnoses were associated with P/LP carrier status for all 4 genes ( KCNE1 OR 22.8, p=1.0e-4; KCNH2 OR 35.1, p=1.8e-7; KCNQ1 OR 27.3, p=3.6e-18; SCN5A OR 5.6, p=0.02). Carriers of SCN5A P/LP variants were also more likely to have PVCs (OR 4.3, p=0.003). Sensitivity analyses showed the associations predated the RoR. EHRs included a diagnosis of LQTS or Brugada Syndrome in 11/71 (16%) pre-RoR, and 16 more were diagnosed after RoR (27/71, 38%). A total of 47/71 (66%) participants had a documented arrhythmia phenotype 1 year after RoR, although 20 of these participants were not diagnosed with an inherited arrhythmia syndrome. Conclusion: Inherited arrhythmia diagnoses could be established in nearly half of participants with P/LP variants. These data indicate that return of incidental P/LP variants in these genes may facilitate the early diagnosis of arrhythmias.
Abstract 13594: Adverse Right Ventricular Remodelling, Function and Stress Responses in Obesity: Implications for Severe Acute Respiratory Illness
Lewis, Andrew J, Moody, William E. , Khan‐Kheil, Ayisha Mehtab , Senior, Jonathan , Abdesselam, Inès, Barker, Graham, Colebourn, Claire, Mahroof, Razeen, Foley, Paul , Lewis, Andrew J, Watson, William, Mahmoud-Elsayed, Hani M. , Rayner, Jennifer J. , Byrne, James Patrick , Borlaug, Barry A. , Neubauer, Stefan , Steeds, Richard Paul , Rider, Oliver J.

Mayo Clinic

Circulation | May 10, 2021 | Volume: 142 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.142.suppl_3.13594 Get It

Introduction: The mechanisms linking obesity to increased mortality in patients with coronavirus-disease 2019 (COVID-19) are unclear. Hypothesis: We hypothesised that obesity would be associated with adverse right ventricular (RV) remodelling and function which might be further exacerbated by COVID-19 associated increases in RV afterload/demand. Methods: We used echocardiography and computed tomography to establish links between RV dimensions and function and bodyweight in patients with severe COVID-19. In obese and non-obese participants without COVID-19, we used cardiovascular magnetic resonance to define the effects of obesity upon RV volumes, energetics, systolic function and stress reserve. Results: In patients with severe COVID-19, increasing bodyweight was associated with disproportionate RV dilatation (n=26, echocardiography, R=0.42, P=0.03, CT n=34, R=0.23, P=0.004) and impairment of RV systolic function (fractional area change (FAC) R=-0.45, P=0.04); obesity (BMI >30kg/m2) was associated with a 32% reduction in RV FAC (P=0.03). Similar associations were seen in a validation cohort (n=91, all P<0.05). In participants without COVID-19, class III obesity (n=54, BMI 47±4 kg/m 2 ) was associated with RV remodelling, impaired cardiac energetics (PCr/ATP ratio 23% lower, P<0.001) and reduction in RV systolic function at rest (by 3±1%, P=0.01), which was related to reduced energetics (R=0.3, P=0.04). Participants with class I-II obesity (BMI 35±5 kg/m 2 , n=27) had impaired RV diastolic filling rate at rest (P<0.001) and blunted RV dobutamine stress systolic response (by 68%, P=0.03) and diastolic response (by 78%, P=0.008). Surgical weight loss in patients obesity (n=37, 34±15kg weight loss) was associated with improvement in RV volume (12±26 ml lower, P=0.006) and function (ejection fraction 2±5% higher, P=0.03). Conclusions: Increasing body weight is associated with both significant alterations in RV volumes, systolic function and stress responses which are mitigated with weight loss and also with disproportionate RV dilatation and dysfunction in severe COVID-19. RV dysfunction is a modifiable mechanism which might link obesity to adverse outcomes in patients with COVID-19 and other disorders stressing the right heart.